CTSO Stock Overview
About the company
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cytosorbents Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.32 |
| 52 Week High | US$4.59 |
| 52 Week Low | US$1.03 |
| Beta | 0.76 |
| 1 Month Change | -5.41% |
| 3 Month Change | 137.14% |
| 1 Year Change | 8.14% |
| 3 Year Change | -45.66% |
| 5 Year Change | -52.91% |
| Change since IPO | -92.41% |
Recent News & Updates
Recent updates
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Mar 08
CytoSorbents secures $4.3M contract by U.S. Department of Defense
Oct 06CytoSorbents stock rises on US DoD contract to develop device for universal plasma
Sep 09We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Sep 02CytoSorbents gets reimbursement for CytoSorb in Turkey
Aug 23CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system
Aug 17Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M
Aug 02We're Not Very Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Mar 03Cytosorbents: Endocarditis Trial Failed To Remove Risk In Heart Surgery Patients
Oct 08Estimating The Intrinsic Value Of Cytosorbents Corporation (NASDAQ:CTSO)
Aug 11Shareholders May Be A Bit More Conservative With Cytosorbents Corporation's (NASDAQ:CTSO) CEO Compensation For Now
May 26Calculating The Fair Value Of Cytosorbents Corporation (NASDAQ:CTSO)
May 05Here's Why We're Not At All Concerned With Cytosorbents' (NASDAQ:CTSO) Cash Burn Situation
Apr 14Cytosorbents Corporation (NASDAQ:CTSO): Are Analysts Optimistic?
Mar 24What You Need To Know About Cytosorbents Corporation's (NASDAQ:CTSO) Investor Composition
Mar 03Introducing Cytosorbents (NASDAQ:CTSO), The Stock That Zoomed 258% In The Last Five Years
Feb 05
CytoSorbents' CytoSorb secures emergency use nod in Canada for use in hospitalized COVID-19 patients
Jan 12Cytosorbents (NASDAQ:CTSO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 10Cytosorbents Corporation (NASDAQ:CTSO) Is Expected To Breakeven In The Near Future
Dec 14Cytosorbents: Concentration Risk With Covid-19 Overexposure
Nov 20Shareholder Returns
| CTSO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.2% | 0.6% | 0.8% |
| 1Y | 8.1% | -13.6% | -14.2% |
Return vs Industry: CTSO exceeded the US Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: CTSO exceeded the US Market which returned -14.2% over the past year.
Price Volatility
| CTSO volatility | |
|---|---|
| CTSO Average Weekly Movement | 17.1% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CTSO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: CTSO's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
Cytosorbents Corporation Fundamentals Summary
| CTSO fundamental statistics | |
|---|---|
| Market Cap | US$144.96m |
| Earnings (TTM) | -US$32.81m |
| Revenue (TTM) | US$34.69m |
4.2x
P/S Ratio-4.4x
P/E RatioIs CTSO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTSO income statement (TTM) | |
|---|---|
| Revenue | US$34.69m |
| Cost of Revenue | US$13.96m |
| Gross Profit | US$20.73m |
| Other Expenses | US$53.55m |
| Earnings | -US$32.81m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 59.77% |
| Net Profit Margin | -94.59% |
| Debt/Equity Ratio | 14.1% |
How did CTSO perform over the long term?
See historical performance and comparison